Aralez Pharma (ARLZ) Posts Wider Q4 Loss, Revenues Beat

Aralez Pharma (NASDAQ: ARLZ) reported Q4 EPS of ($0.68), $0.36 worse than the analyst estimate of ($0.32). Revenue for the quarter came in at $28 million versus the consensus estimate of $25.6 million.

GUIDANCE:

Aralez Pharma sees FY2018 revenue of $140-160 million, versus the consensus of $141.9 million.

For earnings history and earnings-related data on Aralez Pharma (ARLZ) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• L3Harris CEO steps down amid conduct review, shares drop
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance